The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice

Paula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, Emily Reisenbichler, Zuzana Kos, Jodi M Carter, Stefan Michiels, John Le Quesne, Torsten O Nielsen, Anne-Vibeke Laenkholm, Stephen B Fox, Julien Adam, John Bartlett, David L Rimm, Cecily Quinn, Dieter Peeters, Maria V Dieci, Anne Vincent-Salomon, Ian Cree, Akira I HidaJustin M Balko, Harry R Haynes, Isabel Frahm, Gabriel Acosta-Haab, Marcelo Balancin, Enrique Bellolio, Wentao Yang, Pawan Kirtani, Tomohaura Sugie, Anna Ehinger, Carlos A Castaneda, Marleen Kok, Heather McArthur, Kalliopi Siziopikou, Sunil Badve, Susan Fineberg, Allen Gown, Giuseppe Viale, Stuart J Schnitt, Giancarlo Pruneri, Frederique Penault-Llorca, Stephen Hewitt, E Aubrey Thompson, Kimberley H Allison, William F Symmans, Andrew M Bellizzi, Edi Brogi, David A Moore, Denis Larsimont, Deborah A Dillon, Alexander Lazar, Huangchun Lien, Matthew P Goetz, Glenn Broeckx, Khalid El Bairi, Nadia Harbeck, Ashley Cimino-Matthews, Christos Sotiriou, Slyvia Adams, Shi-Wei Liu, Sibylle Loibl, I Chun Chen, Sunil R Lakhani, Jonathan W Juco, Carsten Denkert, Elizabeth F Blackley, Sandra Demaria, Roberto Leon-Ferre, Oleg Gluz, Dimitrios Zardavas, Kenneth Emancipator , Scott Ely, Sherene Loi, Roberto Salgado, Melinda Sanders

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
JournalThe Journal of Pathology
Publication statusPublished - 4 Mar 2020

Cite this